Join to View Full Profile
1245 N Butterfield RdBolivar, MO 65613
Phone+1 417-327-3530
Fax+1 417-327-3543
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Curtis Schreiber, MD is a board certified neurologist in Bolivar, Missouri. He is currently licensed to practice medicine in Missouri and Minnesota.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1987 - 1991
Mayo Clinic College of MedicineClass of 1987
Mayo Clinic College of MedicineClass of 1987
Certifications & Licensure
MO State Medical License 1991 - 2026
MN State Medical License 1988 - 1991
American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 28 citationsMonthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201).Karissa Johnston, Linda Harris, Lauren Powell, Evan Popoff, Vladimir Coric
The Journal of Headache and Pain. 2022-01-17 - The otolaryngologist's challenge: the differential diagnosis of the positive scan.Curtis P. Schreiber
Otolaryngologic Clinics of North America. 2014-04-01 - 80 citationsA Multi-Center Double-Blind Pilot Comparison of OnabotulinumtoxinA and Topiramate for the Prophylactic Treatment of Chronic MigraineRoger Cady, Curtis P. Schreiber, John A. H. Porter, Andrew M. Blumenfeld, Kathleen Farmer
Headache. 2011-01-01
Press Mentions
Bolivar Patients Played a Role in Clinical Trial for a Prospective Alzheimer's TreatmentMay 11th, 2023
Bolivar Neurologist Hopes Clinical Research Will Provide Clues About Alzheimer’sJune 5th, 2020
Bolivar’s Citizens Memorial Hospital Part of Clinical Study for Groundbreaking Alzheimer’s Treatment DrugJuly 21st, 2023










